Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Vincristine, dexamethasone and...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

Bibliographic Details
Main Authors: Patrice Chevallier, Francoise Huguet, Emmanuel Raffoux, Anne Etienne, Thibaut Leguay, Francoise Isnard, Nelly Robillard, Thierry Guillaume, Jacques Delaunay, Aude Charbonnier, Arnaud Pigneux, Pierre Peterlin, Marie C. Bené, William A. Wegener, David M. Goldenberg, Hervé Dombret
Format: Article
Language:English
Published: Ferrata Storti Foundation 2015-04-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/7352
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/7352

Similar Items

  • Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia
    by: Patrice Chevallier, et al.
    Published: (2017-05-01)
  • Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography
    by: Caroline Bodet-Milin, et al.
    Published: (2008-03-01)
  • Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus
    by: Al Rayes H, et al.
    Published: (2014-11-01)
  • Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
    by: Sébastien Maury, et al.
    Published: (2010-02-01)
  • Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
    by: Thomas E. Witzig, et al.
    Published: (2014-11-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs